OncoCyte

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OncoCyte Corporation (OCX) CEO Ronald Andrews on Q3 2019 Results - Earnings Call Transcript

The goals of the collaboration include several key initiatives, including partnerships with clinical trial networks and increasing access to molecular testing for the early diagnosis and management of lung cancer The goals of the collaboration include several key initiatives, including partnerships with clinical trial networks and increasing access to molecular testing for the early diagnosis and management of lung cancer

Oncocyte Announces Strategic Support of GO2 Foundation for Lung Cancer

ALAMEDA, Calif., Oct.  15, 2019  (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a molecular diagnostics company providing actionable answers at critical decision points across the cancer care continuum, today announced the company will present data highlighting its proprietary liquid biopsy test, which has the potential to determine which nodules are benign to reduce the number of unnecessary biopsies and associated complications, during the CHEST Annual Meeting 2019. This year’s CHEST meeting is being held October 19-23, 2019 at the Ernest N. Morial Convention Center in New Orleans, LA.

OncoCyte to Present Data From a Study Examining Its Liquid Biopsy Test During the CHEST Annual Meeting 2019

Early detection of lung cancer has become a national priority in the field of health.

OncoCyte: Promising Future In The Field Of Liquid Biopsy Tests

Acquisition of Razor’s treatment stratification test will broaden OncoCyte's capabilities to include the management of early-stage lung cancer 

OncoCyte Announces Definitive Agreement to Acquire Razor Genomics

OncoCyte Corporation (OCX) CEO Ronald Andrews on Q2 2019 Results - Earnings Call Transcript

Coherus BioSciences

DD3 Acquisition Corp - Units (1 Ord & 1 War)

Floor & Decor Holdings

HD Supply Hlds

Karuna Therapeutics Inc

Motus GI Hlds

The GuruFocus All-in-One Screener can be used to find insider trades from the past week.

Insiders Roundup: OncoCyte, BioSciences

OncoCyte (OCX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

OncoCyte (OCX) Catches Eye: Stock Jumps 7.3%

OncoCyte Corporation (OCX) CEO William Annett on Q1 2019 Results - Earnings Call Transcript

OncoCyte Corporation (OCX) CEO William Annett on Q4 2018 Results - Earnings Call Transcript

Today, we take a look at OncoCyte, a small diagnostic firm on the cusp of commercialization.

OncoCyte: Diagnostic Play Worth A Small $4 Bet

News for OncoCyte Stock (OCX)